Can the U.S. Food and Drug Administration act against global frauds? The extraterritorial effect of Food and Drug Administration sanctions after Small v. United States.
作者信息
O'Reilly James
机构信息
University of Cincinnati College of Law, Cincinnati, OH, USA.
出版信息
Food Drug Law J. 2005;60(3):347-60.
PMID:16304742
Abstract
摘要
相似文献
1
2
Remarks at the Food and Drug Law Institute's 48th Annual Conference.
Food Drug Law J. 2005;60(2):117-26.
3
Criminalizing knowledge: the perverse implications of the intended use regulations of off-label promotion prosecutions.
Food Drug Law J. 2009;64(3):441-58.
4
Why doctors should worry about preemption.
N Engl J Med. 2008 Jul 3;359(1):1-3. doi: 10.1056/NEJMp0804448.
5
WHO launches taskforce to fight counterfeit drugs.
Bull World Health Organ. 2006 Sep;84(9):689-90.
6
Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
Food Drug Law J. 2007;62(3):559-72.
7
Life after Riegel: a fresh look at medical device preemption one year after Riegel v. Medtronic, Inc.
Food Drug Law J. 2009;64(2):291-311.
8
The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
Food Drug Law J. 2008;63(2):391-406.
9
The FDA defense: a prescription for easing the pain of punitive damage awards in medical products liability cases.
Spec Law Dig Health Care Law. 1997 Sep(223):9-45.
10
The FDA, preemption, and the Supreme Court.
N Engl J Med. 2008 May 1;358(18):1883-5. doi: 10.1056/NEJMp0802108.
Zotero 插件